文献速递肝病消化道肿瘤与早癌

肝切除术后GLP-1RA与DPP-4i对肝癌合并2型糖尿病患者的疗效比较:目标试验模拟研究

Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.
PubMed 文献 · Gut · 2026-07-03

该研究采用目标试验模拟方法,基于中国36家医院电子病历数据,纳入1249例接受R0切除的肝细胞癌合并2型糖尿病成人患者,比较术后启用GLP-1RA与DPP-4i的结局。中位随访50.8个月,加权意向性分析显示GLP-1RA组无复发生存期(HR 0.80,95%CI 0.67-0.96;p=0.016)和总生存期(HR 0.58,95%CI 0.47-0.71;p<0.001)均优于DPP-4i组。

要点

  • 肝细胞癌合并2型糖尿病患者术后启用GLP-1RA与更长的无复发生存期相关。
  • GLP-1RA组总生存期显著优于DPP-4i组,HR为0.58。
  • 围手术期用药选择可能影响肝癌切除术后结局。

核心结论

  • 肝切除术后启用GLP-1RA相比DPP-4i与延迟复发和更长总生存期相关,需前瞻性研究确认。

研究设计与样本

  • 纳入组织学确诊肝细胞癌合并2型糖尿病、接受R0切除、术后0至90天启用GLP-1RA或DPP-4i的成人患者。
  • 最终分析队列1249例,其中DPP-4i启用者723例,GLP-1RA启用者526例;中位随访50.8个月。
  • 主要估计量为意向性治疗,预设符合方案分析评估持续依从性;主要结局为无复发生存期,总生存期为次要结局。
  • 研究注册于中国临床试验注册中心(ChiCTR2600118495)。

主要发现

  • 加权意向性治疗分析中,GLP-1RA相比DPP-4i启用与更长无复发生存期相关(病因特异性HR 0.80,95%CI 0.67至0.96;p=0.016)。
  • 加权意向性治疗分析中,GLP-1RA相比DPP-4i启用与更长总生存期相关(HR 0.58,95%CI 0.47至0.71;p<0.001)。
  • 符合方案分析结果方向一致。

临床怎么用

  • 对于肝细胞癌合并2型糖尿病行R0切除的患者,术后降糖方案选择可考虑优先启用GLP-1RA而非DPP-4i以改善生存结局。

局限性

  • 研究为观察性目标试验模拟,可能存在残余混杂,结论需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrence after curative-intent resection remains common in hepatocellular carcinoma (HCC), and whether postoperative incretin-based treatment choice influences outcomes in patients with type 2 diabetes (T2D) is unclear. OBJECTIVE: To determine whether postoperative initiation of glucagon-like peptide-1 receptor agonists (GLP-1RAs), compared with dipeptidyl peptidase-4 inhibitors (DPP-4is), is associated with improved recurrence-free and overall survival after curative-intent resection for HCC. DESIGN: Active-comparator, new-user target trial emulation using electronic medical records from 36 hospitals across China from 2014 to 2023, with follow-up through 1 October 2025. Eligible adults had histologically confirmed HCC and T2D, underwent R0 resection and initiated a GLP-1RA or DPP-4i within postoperative days 0 to 90. Time zero was the first qualifying prescription or order date. The primary estimand was intention-to-treat; a prespecified per-protocol analysis assessed sustained adherence. The primary outcome was recurrence-free survival (RFS), treating death without recurrence as a competing event; overall survival (OS) was secondary. The study was registered with the Chinese Clinical Trial Registry (ChiCTR2600118495). RESULTS: Among 42 855 patients with HCC and T2D who underwent liver resection, 1249 were included in the final analytical cohort, including 723 DPP-4i initiators and 526 GLP-1RA initiators; median follow-up was 50.8 months. In weighted intention-to-treat analyses, GLP-1RA versus DPP-4i initiation was associated with longer RFS (cause-specific HR 0.80, 95% CI 0.67 to 0.96; p=0.016) and OS (HR 0.58, 95% CI 0.47 to 0.71; p<0.001). Per-protocol analyses were directionally consistent. CONCLUSION: Postoperative GLP-1RA initiation, compared with DPP-4i initiation, was associated with delayed recurrence and longer OS; prospective confirmation is warranted. TRIAL REGISTRATION NUMBER: ChiCTR2600118495.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Xiang YJ, Liu ZH, Feng JK, et al. Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study. Gut. 2026. PMID: 42399086. doi:10.1136/gutjnl-2026-338462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。